Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Mixed and Match vs One-size-fits-all

22 mars 2022 uppdaterad av: Dr Katherine Lam, The Hong Kong Polytechnic University

Mixed and Match Versus One-size-fits-all: A Randomized Controlled Trial of Self-determination Theory on a Menu of Smoking Cessation Options (SDTM) Among Adult Smokers

Most existing smoking cessation services are based on '5A's' and '5R's' models which are recognized by the World Health Organization as a standardized tool for smoking cessation. While there are more techniques that are known to be effective and could be incorporated in existing smoking cessation interventions to further promote their effectiveness. This study is to examine the effectiveness SDTM in assisting adult smokers in Hong Kong to quit.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Detaljerad beskrivning

A randomized controlled trial (RCT) will be conducted. One-hundred adult smokers aged 25 or above will be recruited from smoking hotspots in Hong Kong. Participants in the intervention group will be contacted by our trained research assistant to receive a telephone counselling session at baseline. Participants can choose to receive their own smoking cessation treatment options from our menu. Control group participants will only receive a self-help quitting leaflet

Studietyp

Interventionell

Inskrivning (Förväntat)

500

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

25 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • have smoking in the previous 30 days.
  • be above 25 years old
  • able to speak Cantonese and read Chinese

Exclusion Criteria:

  • who are receiving current smoking cessation services
  • report psychological disorders
  • at risk of suicide

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Övrig: Mixed and Match
Participants can choose to receive their own smoking cessation treatment options from our menu.
Participants will receive a brief 15-minute counselling session based on the 5A's' and '5R's' models by our trained research assistant. Participants will be able to choose their smoking cessation treatment options from our menu.
Övrig: Control
Participants will receive a self-help quitting leaflet
Participants in the control group will receive a self-help quitting leaflet issued by the TACO

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Self-reported abstinence at 6-month follow-up
Tidsram: At 6-month follow-up
participants will be asked about their self-reported abstinence in the past 7 and 30 days
At 6-month follow-up
Biochemically validated abstinence
Tidsram: At 6 months follow-up
validate the self-reported abstinence if the level of carbon monoxide in expired air was less than 4 parts per million and saliva cotinine level was less than100 ng/mL in parallel tests
At 6 months follow-up
Self-efficacy at 6-month follow-up
Tidsram: At 6-month follow-up
Participants will be asked about their self-efficacy in quitting. The score ranges from 0 to 10. Higher scores represent a higher self-efficacy.
At 6-month follow-up

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Screening rate
Tidsram: at day 1
calculated as the number of smokers screened at smoking hotspots by the RA divided by number of smokers available
at day 1
Eligibility rate
Tidsram: at day 1
calculated by dividing the number of smokers who are eligible by the number who are screened.
at day 1
Randomization rate
Tidsram: at day 1
calculated by dividing the number of smokers who are randomized into intervention and control groups by those who provide consent.
at day 1
Attendance rate
Tidsram: Immediately after the training workshop
calculated by dividing the number of smokers who complete the intervention by those who are randomized.
Immediately after the training workshop
Retention rate at 1-week follow-up
Tidsram: At 1-week follow-up
calculated by dividing the number of smokers who remain in the study by those who are randomized
At 1-week follow-up
Retention rate at 1-month follow-up
Tidsram: At 1-month follow-up
calculated by dividing the number of smokers who remain in the study by those who are randomized
At 1-month follow-up
Retention rate at 6-month follow-up
Tidsram: At 6-month follow-up
calculated by dividing the number of smokers who remain in the study by those who are randomized
At 6-month follow-up
Retention rate at 3-month follow-up
Tidsram: At 3-month follow-up
calculated by dividing the number of smokers who remain in the study by those who are randomized
At 3-month follow-up
Adherence to intervention protocol at 1-week follow-up
Tidsram: At 1-week follow-up
calculated by dividing the number of smokers who follow and practice the chosen treatment options by those who are randomized
At 1-week follow-up
Adherence to intervention protocol at 1-month follow-up
Tidsram: At 1-month follow-up
calculated by dividing the number of smokers who follow and practice the chosen treatment options by those who are randomized
At 1-month follow-up
Adherence to intervention protocol at 3-month follow-up
Tidsram: At 3-month follow-up
calculated by dividing the number of smokers who follow and practice the chosen treatment options by those who are randomized
At 3-month follow-up
Adherence to intervention protocol at 6-month follow-up
Tidsram: At 6-month follow-up
calculated by dividing the number of smokers who follow and practice the chosen treatment options by those who are randomized
At 6-month follow-up
Complete rate at 1-week follow-up
Tidsram: At 1-week follow-up
calculated by dividing the number of smokers who returned questionnaires by the number of questionnaires distributed
At 1-week follow-up
Complete rate at 1-month follow-up
Tidsram: At 1-month follow-up
calculated by dividing the number of smokers who returned questionnaires by the number of questionnaires distributed
At 1-month follow-up
Complete rate at 3-month follow-up
Tidsram: At 3-month follow-up
calculated by dividing the number of smokers who returned questionnaires by the number of questionnaires distributed
At 3-month follow-up
Complete rate at 6-month follow-up
Tidsram: At 6-month follow-up
calculated by dividing the number of smokers who returned questionnaires by the number of questionnaires distributed
At 6-month follow-up
Missing data at 1-week follow-up
Tidsram: At 1-week follow-up
calculated as the percentage of missing values in the dataset
At 1-week follow-up
Missing data at 1-month follow-up
Tidsram: At 1-month follow-up
calculated as the percentage of missing values in the dataset
At 1-month follow-up
Missing data at 3-month follow-up
Tidsram: At 3-month follow-up
calculated as the percentage of missing values in the dataset
At 3-month follow-up
Missing data at 6-month follow-up
Tidsram: At 6-month follow-up
calculated as the percentage of missing values in the dataset
At 6-month follow-up
Adverse events at 6-month follow-up
Tidsram: At 6-month follow-up
Participants will report any unfavorable and unintended events
At 6-month follow-up
Adverse events at 1-week follow-up
Tidsram: At 1-week follow-up
Participants will report any unfavorable and unintended events
At 1-week follow-up
Adverse events at 1-month follow-up
Tidsram: At 1-month follow-up
Participants will report any unfavorable and unintended events
At 1-month follow-up
Adverse events at 3-month follow-up
Tidsram: At 3-month follow-up
Participants will report any unfavorable and unintended events
At 3-month follow-up
Self-reported abstinence at 1-week follow-up
Tidsram: At 1-week follow-up
Participants will be asked about their self-reported abstinence in the past 7 and 30 days
At 1-week follow-up
Self-reported abstinence at 1-month follow-up
Tidsram: At 1-month follow-up
participants will be asked about their self-reported abstinence in the past 7 and 30 days
At 1-month follow-up
Self-reported abstinence at 3-month follow-up
Tidsram: At 3-month follow-up
participants will be asked about their self-reported abstinence in the past 7 and 30 days
At 3-month follow-up
Self-efficacy at 1-week follow-up
Tidsram: at 1-week follow-up
Participants will be asked about their self-efficacy in quitting. The score ranges from 0 to 10. Higher scores represent a higher self-efficacy.
at 1-week follow-up
Self-efficacy at 1-month follow-up
Tidsram: at 1-month follow-up
Participants will be asked about their self-efficacy in quitting. The score ranges from 0 to 10. Higher scores represent a higher self-efficacy.
at 1-month follow-up
Self-efficacy at 3-month follow-up
Tidsram: at 3-month follow-up
Participants will be asked about their self-efficacy in quitting. The score ranges from 0 to 10. Higher scores represent a higher self-efficacy.
at 3-month follow-up

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Katherine Lam, PhD, The Hong Kong Polytechnic University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Förväntat)

1 juli 2022

Primärt slutförande (Förväntat)

31 december 2023

Avslutad studie (Förväntat)

31 december 2023

Studieregistreringsdatum

Först inskickad

18 maj 2021

Först inskickad som uppfyllde QC-kriterierna

22 mars 2022

Första postat (Faktisk)

28 mars 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

28 mars 2022

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

22 mars 2022

Senast verifierad

1 mars 2022

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera